RC48 is an ADC targeting ERBB2 and has been reported as a promising therapeutic method for treating various cancers, including breast cancer (8), gastric cancer (9), non-small-cell lung cancer (10), and bladder cancer (11). Here, ERBB2 is linked to urinary bladder carcinoma.